Zydus Cadila is in talks with Biochem Pharmaceuticals to acquire the brands and manufacturing facility of the latter. The deal is expected to be valued at around Rs 300-450 crore and will boost Biochem's revenue growth. Zydus Cadila has been on the hunt for companies that are small in size and have specific product pipelines.
Biochem makes popular antibiotics such as Amicin or amikasin, which is used for dermatological treatment. Its other big brands include Ampilox and Biotax, commonly used as anti-infectives. These three drugs contribute close to 50% of the company's revenues. It also has a small portfolio of oncology products. Biochem reported revenues of Rs 241 crore in fiscal 2009-10 and the company exports products to eight countries.
Cadila Pharmaceuticals focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1693.15 |
| Dr. Reddys Lab | 1221.25 |
| Cipla | 1230.75 |
| Zydus Lifesciences | 939.20 |
| Lupin | 2326.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: